Cancers, Vol. 11, Pages 1715: Conversion Surgery with HIPEC for Peritoneal Oligometastatic Gastric Cancer
Conclusion: Conversion surgery, including extended gastrectomy and multi-organ resections followed by HIPEC performed after systemic chemotherapy therapy for GC with PM is justified in downstaged patients with ypT2 and limited (less than P3) PM.
The peritoneal cavity, especially the omentum, is a common site for gastric cancer metastasis, representing advanced disease stage and poor prognosis. Here, we studied the effects of omental tissue on gastric cancer tumor progression in vitro and in vivo. Utilizing in vitro models, we found that omental tissue secreted factors increased gastric cancer cellular growth (by 30–67%, P 8-fold, P 7-fold, P 1.2-fold for oxaliplatin and>1.6-fold for cisplatin, P
Conclusion.High mesothelin expression is correlated with poor outcomes. In addition, mesothelin expression, Lauren classification, and stage are meaningful predictive factors for peritoneal recurrence. Moreover, mesothelin was a significant predictor of a high risk of peritoneal recurrence in patients with stage III gastric cancer.Implications for Practice.This study demonstrates that high mesothelin expression correlates with poor outcomes and is a significant predictor of peritoneal recurrence in patients with stage III gastric cancer. This study provides instrumental evidence for designing anti‐mesothelin antibody‐d...
CONCLUSIONS: Palliative laparoscopic resection of gastric cancer combined with IHPC with oxaliplatin +5-FU has a definite therapeutic effect on gastric cancer with PC, which can achieve a better short-term clinical therapeutic effect and better postoperative quality of life. PMID: 31646813 [PubMed - in process]
ner The management of peritoneal metastases from gastric cancer origin has evolved considerably over the last three decades with the establishment of cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) as efficacious therapies in carefully selected patients. Other approaches such as the use of prophylactic/adjuvant HIPEC in patients who are considered high-risk and those with positive peritoneal cytology will benefit from additional data before being adopted into routine clinical practice. Lastly, there are new and emerging intraperitoneal chemotherapy techniques such as early post-operati...
Conclusions: We identified exosomal miRNAs capable of distinguishing between non-malignant and GC-ascites, showing that the combined use of miR-181b-5p and CEA could improve diagnosis. PMID: 31598373 [PubMed]
ConclusionsWe generated MADOs modelling characteristics and mutated genes of MA tumour cells. A broad range of intrinsic MADO response to conventional chemotherapeutics suggests MADOs are amenable to drug screening.
ConclusionsWe identified ascites-derived circulating miRNAs capable of differentiating non-malignant ascites and GC-ascites, and demonstrated that the combined use of miR-181b-5p and CEA produces the optimal diagnostic yield.Legal entity responsible for the studyThe authors.FundingNational Research Foundation of Korea (NRF).DisclosureAll authors have declared no conflicts of interest.
Sharing a poster presentation done in Medcon2019 by Harika B 1styear PG& DR.ANV Prasad, Associate Professor NRI Institute of Medical Sciences CT Findings: Severe ascites seen. Multiple small enhancing nodules seen in the parietal peritoneum, visceral peritoneum and omentum with predominant pelvic distribution.Heterogeneously enhancing lesion of 3x2.1x1.8cm seen in RIF. Appendix is not seen separately from the lesion. Final Impression of Peritoneal carcinomatosis (pseudomyxoma peritoni) - likely due to mucinous adeno Ca. appendix.Peritoneal carcinomatosis(PC) is the term given to malignant tumour seeding of ...
To the Editor The article by Guo et al presents initial findings for the SEIPLUS study, a randomized clinical trial exploring the value of extensive intraoperative peritoneal lavage (EIPL) for treatment of locally advanced gastric cancer. As highlighted by Levine in an accompanying Invited Commentary, the accrual for this trial occurred during a remarkably short period, and EIPL appears to be a simple, safe, and low-cost method to decrease the peritoneal metastases rates.